Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2026 | $5.00 | Buy | B. Riley Securities |
| 12/3/2025 | $5.50 | Buy | Roth Capital |
HINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, commends the American Medical Association's (AMA) expanding efforts to protect health care professionals from ionizing radiation. In late 2025, the AMA adopted a new policy to strengthen protections for health care professionals and trainees who may face occupational radiation exposure. The policy emphasizes the importance of continued research into the health effects of cumulative exposure to ionizing radiation, the effectiveness of Personal Protection Equipment (PPE), and education and training to minimize occupational r
HINGHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that the Company, both in the USA and in Israel, is not experiencing any business disruption as a result of current geopolitical events. The safety and security of the employees remain its top priority. All personnel continue to operate as usual, and both internal operations and the lead manufacturing partner remain fully functional. Following the recent FDA clearance of LIBERTY, the commercial focus of the Company has been on the U.S. market, managed by its dedicated U.S.-based commercial team headquarter
HINGHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that Tampa General Hospital has become the first health system in Florida to adopt LIBERTY, marking another important milestone following the Company's recent FDA 510(k) clearance. Microbot believes that this reflects early post-clearance momentum for LIBERTY and highlights growing institutional readiness for advanced robotic solutions in peripheral endovascular procedures. The U.S. market for peripheral endovascular procedures encompasses approximately 2.5 million procedures annually, representing a signifi
B. Riley Securities initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.00
Roth Capital initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.50
8-K - Microbot Medical Inc. (0000883975) (Filer)
8-K - Microbot Medical Inc. (0000883975) (Filer)
8-K - Microbot Medical Inc. (0000883975) (Filer)
4 - Microbot Medical Inc. (0000883975) (Issuer)
4 - Microbot Medical Inc. (0000883975) (Issuer)
4 - Microbot Medical Inc. (0000883975) (Issuer)
NORWELL, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced the appointment of Scott R. Burell to its Board of Directors. Scott R. Burell is a seasoned healthcare finance executive with over two decades of experience leading public life sciences companies through complex transactions and growth phases. Currently serving as Chief Financia
HINGHAM, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced the appointment of Christina Bailey as its new Vice President of Sales. A two-time U.S. Olympian with 20 years of medical device sales experience, Ms. Bailey has successfully led commercial teams to achieve sales goals. She will report directly to Harel Gadot, the Company's CEO, President and Chairman. Ms. Bailey has held a variety of sales leadership roles. She has worked with notable companies like Boston Scientific, Abbott, Stryker and Intuitive Surgical that have equipped her with the insights necessary to drive growth and
Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year This Appointment Represents the Company's First Commercial Hire as it Ramps Up Commercial Readiness in Anticipation of FDA Clearance during the Second Quarter of 2025 BRAINTREE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the appointment of Paul Mullen, a seasoned medical device sales expert in the Endovascular space, to the newly created role of Vice President of Sales. Mr. Mullen has an extensive track record in sales, market developm
SC 13G/A - Microbot Medical Inc. (0000883975) (Subject)
SC 13G - Microbot Medical Inc. (0000883975) (Subject)